• Monday, April 10, 2023 @ 12:00 am

Reverse share split proposed at EGM to meet NASDAQ listing criteria. Olpruva US launch in early July. US launches of PKU GOLIKE and Olpruva boost near-term revenue. Successful development of pipeline drugs, including RLF-100 in rare lung disease, RLF-OD032 in PKU, and RLF-TD011 in EB, boost long-term revenue.

Key catalysts include:

  • US launch of Olpruva in UCDs (early July 2023)
  • RLF-100 INHALED start of phase IIb sarcoidosis trial (Q2/Q3 2023)
  • EU filing of Olpruva/ACER-001 in UCDs (H2 2023)

To the full Valuation Report

You may also be interested in